1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Brazil Pharmaceuticals and Healthcare Report Q4 2015

Brazil Pharmaceuticals and Healthcare Report Q4 2015

  • September 2015
  • -
  • Business Monitor International
  • -
  • 121 pages

Includes 3 FREE quarterly updates

BMI View: Continued focus on foreign investment along with the expansion of telemedicine andgovernmental action to improve medical access will keep Brazil and appealing destination for drugmakersand healthcare companies in coming years, particularly as the healthcare market remains an outperformerin the country . This appeal, however, will remain limited in the short to medium term as Brazil's troubledeconomy begins to negatively impact other industries including the healthcare and pharmaceutical industrywhich are beginning to experience budget cuts and revenue decreases.

Headline Expenditure ProjectionsPharmaceuticals:

BRL62bn (USD26bn) in 2014 to BRL66bn (USD21bn) in 2015; +6.4% in local currencyterms and -19.5% in US dollar terms. Forecast in has been maintained from Q315.Healthcare: BRL501bn (USD213bn) in 2014 to BRL538bn (USD173bn) in 2015; +7.4% in local currencyterms and -18.7% in US dollar terms. Forecast in local currency has been revised downward fromQ115 due to historic data.

Table Of Contents

Brazil Pharmaceuticals and Healthcare Report Q4 2015
BMI Industry View 7
SWOT 9
Political 11
Economic 12
Operational Risk 13
Industry Forecast 15
Pharmaceutical Market Forecast 15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Brazil 2011-2019) 16
Healthcare Market Forecast 17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2011-2019) 19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2011-2019) 19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2011-2019) 19
Prescription Drug Market Forecast 20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Brazil 2011-2019) 21
Patented Drug Market Forecast 22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Brazil 2011-2019) 23
Generic Drug Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Brazil 2011-2019) 26
OTC Medicine Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Brazil 2011-2019) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Brazil 2013-2019) 31
Table: Pharmaceutical Trade Data And Forecasts local currency (Brazil 2013-2019) 31
Key Risks To BMI's Forecast Scenario 32
Macroeconomic Forecasts 35
Economic Analysis 35
Table: GDP By Expenditure (Brazil 2012-2019) 40
Industry Risk Reward Indices 41
Americas Risk/Reward Index - Q4 2015 41
Brazil Risk/Reward Index 47
Rewards 47
Risks 47
Market Overview 49
Industry Trends And Developments 50
Epidemiology 50
Healthcare Sector 52
Table: Healthcare Resources (Brazil 2009-2014) 53
Table: Healthcare Personnel (Brazil 2009-2014) 53
Table: Healthcare Activity (Brazil 2009-2014) 54
Research and Development 54
Biotechnology 56
Clinical Trials 57
Regulatory Development 59
Competitive Landscape 66
Table: Top 10 Pharmaceutical Companies In Brazil By Sales In 2013 66
Generic Drugmakers 69
Pharmaceutical Distribution Sector 71
Pharmaceutical Retail Sector 73
Company Profile 75
Ache/Biosintetica 75
EMS Sigma 79
Eurofarma 82
Medley 85
Cristália 88
Sanofi 91
Pfizer 94
Merck and Co 97
Novartis 100
GlaxoSmithKline 103
Table: GlaxoSMITHKLINE'S Strong Collaborative Efforts In Public-Private Partnerships (Ppps) In Brazil 105
Roche 107
Demographic Forecast 110
Table: Population Headline Indicators (Brazil 1990-2025) 111
Table: Key Population Ratios (Brazil 1990-2025) 111
Table: Urban/Rural Population and Life Expectancy (Brazil 1990-2025) 112
Table: Population By Age Group (Brazil 1990-2025) 112
Table: Population By Age Group % (Brazil 1990-2025) 113
Glossary 115
Methodology 117
Pharmaceutical Expenditure Forecast Model 117
Healthcare Expenditure Forecast Model 117
Notes On Methodology 118
Risk/Reward Index Methodology 119
Index Overview 120
Table: Pharmaceutical Risk/Reward Index Indicators 120
Indicator Weightings 121

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.